Skye Bioscience Shares Slide as Weight-Loss Drug Candidate Misses Primary Endpoint

Dow Jones10-06

By Adriano Marchese

Skye Bioscience shares fell sharply Monday in premarket trading after the company said its weight-loss drug didn't meet its clinical targets.

Shares traded 60% lower at $1.91 ahead of the morning bell.

The clinical-stage biotechnology company on Monday said top-line data from its Phase 2a CBeyond proof-of-concept study of the compound nimacimab didn't meet primary weight-loss endpoints as a stand-alone therapy.

The San Diego company also said combining nimacimab with semaglutide, the active ingredient in Ozempic and Wegovy used to treat type 2 diabetes, led to significantly greater weight loss at 26 weeks compared with semaglutide alone. Skye said this finding supports potential further studies to evaluate combinations of nimacimab and incretin-based therapies.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

October 06, 2025 07:41 ET (11:41 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2573671720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573671720","market":"hk","top_or_hot":-1,"title":"Skye Bioscience Shares Slide as Weight-Loss Drug Candidate Misses Primary Endpoint","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SKYE\">Skye Bioscience</a> shares fell sharply Monday in premarket trading after the company said its weight-loss drug didn't meet its clinical targets. \n</p>\n<p>\n  Shares traded 60% lower at $1.91 ahead of the morning bell. \n</p>\n<p>\n  The clinical-stage biotechnology company on Monday said top-line data from its Phase 2a CBeyond proof-of-concept study of the compound nimacimab didn't meet primary weight-loss endpoints as a stand-alone therapy. \n</p>\n<p>\n  The San Diego company also said combining nimacimab with semaglutide, the active ingredient in Ozempic and Wegovy used to treat type 2 diabetes, led to significantly greater weight loss at 26 weeks compared with semaglutide alone. Skye said this finding supports potential further studies to evaluate combinations of nimacimab and incretin-based therapies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 06, 2025 07:41 ET (11:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Skye Bioscience Shares Slide as Weight-Loss Drug Candidate Misses Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSkye Bioscience Shares Slide as Weight-Loss Drug Candidate Misses Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-06 19:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SKYE\">Skye Bioscience</a> shares fell sharply Monday in premarket trading after the company said its weight-loss drug didn't meet its clinical targets. \n</p>\n<p>\n  Shares traded 60% lower at $1.91 ahead of the morning bell. \n</p>\n<p>\n  The clinical-stage biotechnology company on Monday said top-line data from its Phase 2a CBeyond proof-of-concept study of the compound nimacimab didn't meet primary weight-loss endpoints as a stand-alone therapy. \n</p>\n<p>\n  The San Diego company also said combining nimacimab with semaglutide, the active ingredient in Ozempic and Wegovy used to treat type 2 diabetes, led to significantly greater weight loss at 26 weeks compared with semaglutide alone. Skye said this finding supports potential further studies to evaluate combinations of nimacimab and incretin-based therapies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 06, 2025 07:41 ET (11:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SKYE","symbol_name":"Skye Bioscience Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2573671720","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573671720","pubTimestamp":1759750860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Skye Bioscience shares fell sharply Monday in premarket trading after the company said its weight-loss drug didn't meet its clinical targets.Shares traded 60% lower at $1.91 ahead of the morning bell.The clinical-stage biotechnology company on Monday said top-line data from its Phase 2a CBeyond proof-of-concept study of the compound nimacimab didn't meet primary weight-loss endpoints as a stand-alone therapy.The San Diego company also said combining nimacimab with semaglutide, the active ingredient in Ozempic and Wegovy used to treat type 2 diabetes, led to significantly greater weight loss at 26 weeks compared with semaglutide alone. Skye said this finding supports potential further studies to evaluate combinations of nimacimab and incretin-based therapies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SKYE":"Skye Bioscience Inc.","BK4139":"生物科技"},"translate_title":"由于减肥候选药物未达到主要终点，Skye Bioscience股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SKYE":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\nSkye Bioscience shares fell sharply Monday in premarket trading after the company said its weight-loss drug didn't meet its clinical targets. \n\n\n  Shares traded 60% lower at $1.91 ahead of the morning bell. \n\n\n  The clinical-stage biotechnology company on Monday said top-line data from its Phase 2a CBeyond proof-of-concept study of the compound nimacimab didn't meet primary weight-loss endpoints as a stand-alone therapy. \n\n\n  The San Diego company also said combining nimacimab with semaglutide, the active ingredient in Ozempic and Wegovy used to treat type 2 diabetes, led to significantly greater weight loss at 26 weeks compared with semaglutide alone. Skye said this finding supports potential further studies to evaluate combinations of nimacimab and incretin-based therapies. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 06, 2025 07:41 ET (11:41 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2573671720","isCrawlerRequest":true}